• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ETHZilla Corporation filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    9/15/25 8:04:24 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ETHZ alert in real time by email
    false 0001690080 0001690080 2025-09-15 2025-09-15 0001690080 ETHZW:CommonStockParValue0.0001PerShareMember 2025-09-15 2025-09-15 0001690080 ETHZW:WarrantsToPurchaseSharesOfCommonStockMember 2025-09-15 2025-09-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): September 15, 2025

     

    ETHZilla Corporation

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware   001-38105   90-1890354
    (State or Other Jurisdiction
    of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    2875 South Ocean Blvd, Suite 200

    Palm Beach, FL

      33480
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (650) 507-0669

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   ETHZ   The NASDAQ Stock Market LLC
    Warrants to purchase shares of Common Stock   ETHZW   The NASDAQ Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 7.01 Regulation FD Disclosure.

     

    On September 15, 2025, ETHZilla Corporation (the “Company”) issued a press release providing an update on its stock repurchase program, business strategy, and ETH accumulation, a copy of which is furnished hereto as Exhibit 99.1, which is incorporated by reference into this Item 7.01 in its entirety.

     

    The information in this Item 7.01 of this Current Report on Form 8-K, including the information contained in Exhibit 99.1 is being furnished to the U.S. Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

     

    Item 8.01 Other Events.

     

    Stock Repurchase Program

     

    On August 22, 2025, the Board of Directors of the Company authorized and approved a stock repurchase program for up to $250.0 million of the currently outstanding shares of the Company’s common stock. Subject to any future extension in the discretion of the Board of Directors of the Company, the repurchase program is scheduled to expire upon the earliest of (i) June 30, 2026, (ii) when a maximum of $250.0 million of the Company’s common stock has been repurchased, or (iii) when such program is discontinued by the Board of Directors.

     

    From September 5, 2025 to September 12, 2025, the Company repurchased an aggregate of approximately 3.75 million shares of common stock at an average price of $2.50 per share, which have been cancelled and/or in the process of being cancelled.

     

    ETH Accumulation Status Update

     

    A summary of ETHZilla’s current ETH position and key metrics as of September 12, 2025:

     

      ● Total ETH & ETH Equivalents Held: 102,255

     

      ● Total ETH & ETH Equivalents Held (USD): approximately $460 million

     

      ● Total USD Cash Equivalents: approximately: $228 million

     

      ● Total Earned Protocol Tokens: 1,500,000
         
      ● Total Shares Outstanding: 160,676,122

     

    1

     

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description of Exhibit
    99.1*   Press Release dated September 15, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL documents).

     

    * Furnished herewith.

     

    Forward Looking Statements

     

    This Current Report on Form 8-K and the press release attached as Exhibit 99.1 to this Current Report on Form 8-K, may contain forward-looking information within the meaning of applicable securities laws (“forward-looking statements”). These forward-looking statements represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target” or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company’s control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, including, the amount and timing of stock repurchases under the repurchase program. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to the fact that common share repurchases may not be conducted in the timeframe or in the manner the Company expects, or at all. The Company undertakes no obligation to publicly update or revise any of the forward-looking statements, whether because of new information, future events or otherwise, made in the release or presentation or in any of its Securities and Exchange Commission (SEC) filings or public disclosures, except as provided by law. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties. More information on potential factors that could affect the Company’s financial results is included from time to time in the “Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s periodic and current filings with the SEC, including Form 10-Qs, Form 10-Ks and Form 8-Ks, filed with the SEC and available at www.sec.gov. Forward-looking statements speak only as of the date they are made.

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: September 15, 2025

     

      ETHZilla Corporation
       
      By:  /s/ McAndrew Rudisill
        Name:  McAndrew Rudisill
        Title: Chief Executive Officer

     

     

    3

     

     

    Get the next $ETHZ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ETHZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ETHZ
    SEC Filings

    View All

    ETHZilla Corporation filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ETHZilla Corp (0001690080) (Filer)

    9/30/25 8:00:55 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: ETHZilla Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K/A - ETHZilla Corp (0001690080) (Filer)

    9/24/25 9:22:57 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ETHZilla Corp (0001690080) (Filer)

    9/22/25 9:25:42 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETHZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ETHZilla to Deploy Approximately $47 Million in ETH to Puffer

    Partnership will include integration of Puffer's validator stack with ETHZilla's treasuries to restake ETH under the Puffer model GEORGE TOWN, Cayman Islands, Sept. 27, 2025 (GLOBE NEWSWIRE) -- Puffer Finance, the leading innovator in Ethereum infrastructure and based rollups, has announced a strategic partnership with ETHZilla, which will see ETHZilla deploy approximately $47 Million in ETH to Puffer. The partnership is geared towards setting a new standard for institutional participation in Ethereum, focusing on restaking with an emphasis on security and performance. ETHZilla selected Puffer for its unique framework, which delivers high yield via restaking, anchored by Puffer's 2 ETH

    9/27/25 2:50:37 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla to Deploy Approximately $47 Million in ETH to Puffer

    Deployment expected to enhance yields on ETHZilla's ETH treasury holdings through restaking PALM BEACH, Fla., Sept. 25, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ: ETHZ) ("ETHZilla" or the "Company"), today announced plans to deploy into the decentralized finance (DeFi) ecosystem approximately $47 million of Ether ("ETH"), representing approximately 10,6001 ETH, to Puffer, a liquid restaking protocol, pursuant to which the Company expects to generate higher yields on its ETH treasury holdings. Puffer Partnership Details Puffer was selected for its ability to deliver hig

    9/25/25 8:00:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla Announces $350 Million Add-On Convertible Debenture Investment and Provides Business Update

    PALM BEACH, Fla., Sept. 22, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ) ("ETHZilla" or the "Company"), today announced a $350 million convertible debenture by an institutional investment partner.  Convertible Debenture Investment Details ETHZilla partnered with the existing convertible debenture investor to amend the terms of the existing convertible debenture and to raise an additional $350 million through the issuance of new convertible debentures (the "New Debentures"). The previously issued $156.5 million convertible debentures will remain at 0% interest until

    9/22/25 8:00:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care